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A B S T R A C T
Background and Aim: The global rise of antimicrobial resistance among bacterial strains is a rapidly
growing challenge and is becoming a major public health concern. This study documents the worldwide
spread and genotype distribution of human clinical isolates of New Delhi metallo-β-lactamase-producing
Klebsiella pneumoniae (NPKP).
Methods: Several international databases, including Web of Science, Embase and Medline were searched
(2010 - 2019) to identify studies addressing the frequency of NPKP regionally or worldwide.
Results: Of 4779 articles identified, 202 studies fulfilled the eligibility criteria and were included in our
analysis. The frequency of NPKP in Asia, Europe, America, Africa and Oceania was 64.6%, 20.1%, 9.0%, 5.6%
and 0.4%, respectively. The most prevalent sequence types (STs) among NPKP were ST11, ST290, ST147,
ST340, ST15, ST278 and ST14 based on published studies.
Conclusion: The dissemination of blaNDM variants in different STs among NPKP in the various region of
world is a serious concern to public health. The prevalence of NPKP should be controlled by
comprehensive infection control measures and optimization of antibiotic therapy.
© 2020 Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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. Introduction
The rise of antibiotic-resistant bacteria is a serious threat to
lobal health [1]. This resistance causes difficulties in proper
ntibiotic treatment of patients suffering from a variety of
nfections. Carbapenems are a group of beta-lactam antibiotics
sed to treat infections caused by extended-spectrum beta-
actamase (ESBL)-producing bacteria [2,3]. According to many
eports, resistance to these antibiotics in gram-negative bacteria
as become epidemic or even pandemic, and is still growing in
agnitude. There are many countries that reported the presence of
arbapenem resistant gram-negative bacteria in a variety of
linical settings. India [4], China [5], Pakistan [6], Greece [7],
urkey [8], Peru [9], Mexico [10] and Brazil [11] are among these
ountries.
Hydrolysis of carbapenems by carbapenemase enzymes is the
ain mechanisms of resistance [12–14]. There are four groups (i.e.,
, B, C, D) of beta-lactamase enzymes according to the Ambler
lassification system [13,15]. Carbapenemases are present in
lasses A, B, and D. Carbapenemase-producing bacterial species
uch as members of the order of Enterobacterales are the most
mportant causes of carbapenem resistant infection worldwide
17]. In 2017, the World Health Organization (WHO) announced a
ist of international priority pathogens, including antibiotic
esistant Enterobacterales [18] including Escherichia coli (E. coli)
nd Klebsiella pneumoniae (K. pneumoniae) [19–21]. K. pneumoniae
s a gram-negative opportunistic pathogen that causes many
ifferent diseases including nosocomial infections involving
rinary tract infections, bacteremia, pneumonia, liver abscess
nd others [22,23]. Beta-lactam antibiotics such as carbapenems
nd aminoglycosides are used to control and treat infections
aused by this pathogen [24]. However, a significant proportion of
. pneumoniae strains from clinical origin have become resistant to
hese antibiotics by acquiring resistance genes such as the New
elhi metallo-beta-lactamase (NDM) gene (blaNDM) [25]. Current-
y, 24 NDM variants have been characterized from more than 60
pecies of 11 bacterial families [26]. Members of the NDM family
re among the most common carbapenemases which are usually
ransmitted through horizontal transfer of plasmids [25,27]. Based
n available data the highest frequency of NDM-producing bacteria
re reported across the following continents and countries : China
nd India (Asia) [28,29], Brazil (America) and Algeria (Africa),
ulgaria, Italy, Turkey, Germany, Greece, Romania, Poland, France,
erbia, the UK and Ukraine (Europe) [30,31]. Moreover, numerous
tudies have shown that different variants of blaNDM including
laNDM-1, blaNDM-5 and blaNDM-7 are distributed in different
sequences types (ST) [32,33]. Multi-locus Sequence Typing (MLST)
is a method based on nucleotide sequencing that describes the
genetic relationships between bacterial isolates. For this method,
usually 5–7 well-conserved, house-keeping genes or loci within
the bacterial genome are sequenced and based on its results, allelic
variants in conserved genes of bacterial species are identified [34].
By this method, different STs have been reported for various
isolates of NDM-producing K. pneumoniae (NPKP) worldwide. It is
important to be able to identify the most common STs to improved
infection control programs on a global scale. The purpose of this
study was to evaluate the worldwide spread and genotype
distribution of human clinical isolates of NPKP based on published
studies..
2. Methods
2.1. Search strategy and selection criteria
In the present study, we reviewed original research articles
published in public databases from 2010 to 2019. These databases
include Medline (via PubMed), Embase, and Web of Science.
‘Klebsiella pneumoniae’ or ‘K. pneumoniae and ‘New Delhi metallo-
β-lactamase’ or ‘NDM’ or ‘blaNDM’ were the terms used in our search
strategy. Searches were limited to original articles on the
epidemiology of blaNDM variants in strains isolated from human
specimens. These studies were carried out in different parts of the
world. Additionally, we searched the bibliographies of the relevant
publications selected to identify further studies in this field.
2.2. Inclusion and exclusion criteria
Only studies on human clinical samples with complete
information on the frequency of NPKP were evaluated. These data
included the frequency of blaNDM, country of origin and assessment
methods used. The information in each study was evaluated on the
basis of titles and abstracts first, and at the full text level when the
study seemed pertinent to our analysis. Studies that qualified for
inclusion are [1] original articles with sufficient information on the
frequency of NPKP isolated from humans; [2] studies that used
molecular techniques to detect blaNDM and presented data
regarding the number of patients enrolled. Exclusion criteria
include: [1] studies on non-human cases [2], investigations on
NDM-producing bacteria other than K. pneumoniae, [3] articles
that examined other types of carbapenemases [4], meta-analyses,
systematic reviews and review articles [5], abstracts presented in
conferences, and [6] duplicate publications of the same
able 1
revalence of New Delhi metallo-β-lactamase (NDM)-producing Klebsiella pneumoniae isolated from clinical samples in different continents.
Continent NDM type [n (%)] Total Na
Asia NDM-1(1370, 87), NDM-4(15, 0.9), NDM-5(163, 10.3),NDM-6(13, 0.8), NDM-7(8, 0.5), NDM-9(2, 0.1), NDM-10(1, 1573
0.06), NDM-19(1, 0.06)
Europe NDM-1(489, 99), NDM-5(2, 0.4) 491
America NDM-1(216, 97.7), NDM-5(2, 0.9), NDM-7(3, 1.3) 221
Africa NDM-1(127, 92.7), NDM-2(1, 0.7), NDM-5(6, 4.3), NDM-7(3, 2.2) 137
Oceania NDM-1(10, 100) 10
All continents NDM-1(2212, 90.9), NDM-2(1,0.04), NDM-4(15, 0.6), NDM-5(173, 71), NDM-6(13, 0.5), NDM-7(14, 0.5), NDM-9(2,
0.08), NDM-10(1, 0.04), NDM-19(1, 0.04)
2432
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exclusion criteria and selected the most appropriate articles.
2.3. Data extraction and definitions
The following items were extracted from each of the studies
that met the inclusion criteria: the first author's last name, time of
study, year of publication, country, numbers of K. pneumoniae and
NPKP isolates; type of blaNDM variants in K. pneumoniae isolates; ST
of isolates; source of samples and blaNDM detection techniques
(publications using genotypic identification methods). In order to
render data extraction highly accurate, this was done by two
independent individuals and confirmed by a third researcher. In
order to reach a comprehensive view and solve discrepancies, the
reviewers participated in a final joint discussion (Table1).
3. Results
3.1. Characteristics of included studies
After an initial review of electronic resources and databases, a
total of 5586 articles were collected. Of these, 807 were duplicate
articles occurring in multiple databases and were deleted.
Eventually 4779 unique articles remained. Based on the evaluation
of titles and abstracts, 4503 articles were excluded. Of 276
remained articles, 74 were excluded after full text reading. The
reasons for this removal are given in Fig. 1. Finally, there were 202
articles that met the inclusion criteria of this study and were
selected for final observational and statistical analyses. Of these
202 studies, 110 reports involved the Asian continent, 55 were
European, 19 American, 16 African, and the 2 fin. l studies covered
Oceania. In several studies, NPKP frequency has been reported in
multiple countries. In the supplementary file (Table S1), the main
features of the 202 selected articles are summarized. Based on the
information in this table, most of the articles reviewed in this study
were from China (39 articles) and India (21 articles), respectively.
We found that no studies on NPKP were published before 2010.
Most of the researches included in current analysis were published
between 2016 and 2019 (more than 50%). Based on published
studies, the frequency of NPKP in different continents, including
blaNDM-1, blaNDM-2, blaNDM-4, blaNDM-5, blaNDM-6, blaNDM-7, blaNDM-9,
blaNDM-10, and blaNDM-19 variants are illustrated in Table 2 and
Fig. 2.
As shown in Fig. 3, the 4 most common variants of blaNDM in K.
pneumoniae strains isolated from human samples were blaNDM-1,
blaNDM-5, blaNDM-4 and blaNDM-7. Two studies reported blaNDM-9.
blaNDM-2, blaNDM-10 and blaNDM-19 were each reported in one study.
There were no studies on the frequency of blaNDM-3, blaNDM-8 and
blaNDM-11 to blaNDM-18 among the evaluated studies, suggesting
that these gene variants were rarely reported and may represent
occasional mutants. Table 3 shows the distribution of STs of clinical
NPKP in different parts of the world. The most common samples
which were assessed in the included studies were blood with 25
studies, rectal swabs [24], urines [13], sputa [8], stools [2], perianal
swabs [1] and gastric fluids [1] (Table S1). Typing of NPKP strains in
most of eligible studies was performed by PCR and sequencing as
well as MLST and pulsed-field gel electrophoresis (PFGE)
(Table S1).
3.2. blaNDM variants among K. pneumoniae strains isolated from
human clinical samples from different continents based on published
studies
The frequency of NPKP in different continents is shown in
Table S1. Tables 4,5 and S2 and Fig. 4 show the distribution of the
number of reported NPKP isolates across continents. Except for
blaNDM-2, all blaNDM variants we have mentioned have been
reported in Asia. The highest frequency of NPKP among Asian
countries was encountered in China (44.1%; 695/1573), India
(15.2%; 239/1573), Saudi Arabia (9.6%; 152/1573) and Iran (7.8%;
123/1573%). The results of studies published in Asian countries

















M. Safavi, N. Bostanshirin, B. Hajikhani et al. / Journal of Global Antimicrobial Resistance 23 (2020) 420–429ontinent are observed for blaNDM-1, blaNDM-5, blaNDM-4, and blaNDM-
at 90.1 % (2212/2432), 7.1% (173/2432), 0.6% (15/2432) and 0.5%
14/2432), respectively. Studies show the presence and frequency
f blaNDM-1 in all countries of Asia that are mentioned in Table 4.
blaNDM-5 and blaNDM-7 are the most common variants on the
American continent. blaNDM-1 has been observed in the United
States of America (USA) (70.1%; 155/221), Mexico (21.7%; 48/221),
Canada (3.1%; 7/221), Brazil (2.2%; 5/221) and Chile (0.4; 1/221). As
shown in the Table S2, blaNDM-5 (0.9%; 2/221) is only detected in the
United States and also, blaNDM-7 is only reported in two countries
(USA and Canada) of the American continent. Studies from the
African continent show that blaNDM-1 has been reported in all
countries except for Gabon, related data are mentioned in Table S2.
As mentioned in this Table, blaNDM-2, blaNDM-5 and blaNDM-7 have
been observed only in Egypt (0.7%; 1/137), Angola (4.3%; 6/137) and
Gabon (2.1%; 3/137), respectively. In Oceania, blaNDM-1 was
reported in both Australia (90.0%; 9/10) and New Zealand
(10.0%; 1/10) (Table S2). Fig. 5 shows the serial trend in NPKP
emergence. As shown in this figure, the frequency of NPKP has
been increasing from 2009 to 2012, though in 2013 there was a
downward trend. The frequency of NPKP was highest in 2014-2016.
This abundance has been declining since 2017 until now.
3.3. Most prevalent sequence types among NPKP strains found on
different continents based on published studies
The studies show that for NPKP isolated from clinical specimens
in different countries, 86 unique STs have been reported (Table S3).
The number of STs reported in Asia, Europe, the Americas, Africa,
and Oceania were 43, 10, 11, 17, and 5, respectively. Obviously, these
figures do depend on the number of strains analyzed. ST11 (191
isolates), ST290 (69 isolates), ST147 (61 isolates), ST340 (32
isolates), ST15 (29 isolates), ST278 (25 isolates), ST14 (20 isolates)
were the most commonly reported STs among NPKP (Table S3).
STs11 and ST15, ST147 and ST340 have been reported on all
continents except America, Oceania and Africa, respectively. Still
these can be considered globally occurring clones. ST290 was
reported only in Asia. ST278 was detected in Asia and America.
ST14 has been reported in studies on the continents of Asia, Europe
and Oceania. The frequency of STs reported in different countries is
illustrated in Table S3. Various studies have shown different results
regarding the diversification of STs. Accordingly, China showed the
most diverse range of STs with 48 types. ST11, ST147, ST15, ST340
and STs14 and 307 have been observed in the highest number of
countries. Also, 69 of the 86 (80.2%) STs were only reported in one
country. Figs. 6 and 7 illustrate the frequency of different STs
detected among NPKP isolated from clinical samples from different
continents and countries. Fig. 8 presents the frequency of STs
carrying variants of blaNDM in K. pneumonia isolates around the
world. Also, the most common STs in each country are shown in
Fig. 9.
able 2
istribution of sequence types (STs) among various New Delhi metallo-β-lactamase
NDM) variants in different continents.
Continent NDM-1 (N) NDM-5 (N) NDM-7 (N)
Asia ST1 (2), ST5 (1), ST6 (1), ST11 (27) ST1 (1) ST147 (1) ST76 (1)
ST13 (2), ST14 (10), ST15 (20) ST258 (1)
ST17 (14), ST20 (23), ST25 (6) ST307 (1)
ST29 (1), ST36 (1), ST37 (15) ST340 (1)
ST38 (1), ST45 (1), ST48 (1) ST290 (67)
ST54 (1), ST76 (12), ST86 (1)
ST101 (2), ST105 (1), ST147 (14)
ST152 (12), ST188 (1), ST199 (1)
ST218 (1), ST231 (1), ST234 (2)
ST237 (1), ST273 (6), ST278 (23)
ST290 (2), ST307 (4), ST334 (2)
ST340 (7), ST348 (1), ST367 (1)
ST392 (2), ST395 (1), ST397 (1)
ST372 (1), ST412 (1), ST414 (3)
ST433 (1), ST437 (2), ST483 (1)
ST551 (1), ST500 (1), ST700 (1)
ST826 (1), ST846(1), ST888(1)
ST1035 (1), ST1045 (1), ST1198 (1)
ST1318 (3), ST1383 (1), ST1412 (4)
ST1473 (1), ST1476 (1), ST1641 (1)
ST1636 (1), ST1699 (1), ST1764 (7)
ST2735 (9), ST2736 (2)
Europe ST11 (161), ST14 (7), ST15 (6)
ST16 (3), ST45 (1), ST147 (2)
ST258 (2), ST301 (1), ST307 (1)
ST340 (21)
America ST22 (3), ST37 (1), ST76 (1) ST278 (2)
ST147 (2), ST340 (1)
ST1067 (1), ST1773 (1)
ST1588 (1), ST3371 (1)
ST3372 (1)
Africa ST11 (2), ST15 (1) ST273 (2)
ST101 (14), ST147 (42) ST307 (1)
ST307 (3), ST323 (1) ST414 (2)
ST2016 (1), ST2017 (3) ST1031 (1)
ST3485 (1), ST3486 (1)
ST3487 (1), ST3488 (1)
ST3490 (1), ST3491 (1)
Oceania ST11 (1), ST14 (3), ST15 (2)
ST256(2), ST340 (2)
ig. 2. Frequency of NDM-producing K. pneumoniae in different continents based
n published studies.
Fig. 3. The number of NDM variants in K. pneumoniae strains isolated from human
clinical samples around the world based on published studies.laNDM-19 is reported only in China and blaNDM-10 only in India
Table 3). As shown in Table 5, the common variants in Europe are
laNDM-1 and blaNDM-5. The most reported blaNDM variants in
uropean countries were in Turkey (18.9%; 93/491), Greece (15.8%;
8/491), Bulgaria (13.2%; 65/491), Estonia (10.3%; 51/491) and the
ussia (6.9%; 34/491) (Table 4). According to Table S2, blaNDM-1,424. Discussion
To the best of our knowledge, this is the first report on the global
frequency of NPKP from human clinical samples. We also detail the
occurrence of NPKP STs in different geographical locations.3
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frequency of blaNDM among K. pneumoniae strains isolated from
clinical samples since 2009 until now. This review evaluates 2432
NPKP strains from 53 countries between 2010 and 2019. The
studies show that most of the NPKP are from the Asian continent
with a focus on China, India, and Saudi Arabia with 44.1% and 15.2%
prevalence for China and India. The frequency of blaNDM among K.
pneumoniae strains in Europe was found to be at 20.1%. In the
Americas, the percentage of NPKP was 9.0%. This is 5.6% in Africa,
with the highest frequency in South Africa. In Oceania, the
frequency was 0.4%. The most common variants of blaNDM are
blaNDM-1, blaNDM-5, blaNDM-4 and blaNDM-7. blaNDM-1 - the most
common variant of blaNDM- has been reported in all countries of 5
continents except Gabon (mentioned in Tables 4,5 and S2). Of the 4
common blaNDM variants listed above, only blaNDM-1 has been
reported in Oceania. The highest frequency of blaNDM-1 in Oceania
has been observed in Australia. The results show that blaNDM-4,
blaNDM-6, blaNDM-9, blaNDM-10 and blaNDM-19 have been reported
only in Asia. The results of current study were in accordance with
findings obtained by Khan et al. in 2017 [35]. In their study, Asia
serves as the main reservoir of NDM producers with about 58%
Table 3
Distribution of New Delhi metallo-β-lactamase (NDM)-producing Klebsiella pneumoniae isolated from clinical samples in different countries of Asia.
Country NDM type [n (%)] Total Na
China NDM-1(524, 75.3), NDM-5(157, 22.5), NDM-6(10, 1.4), NDM-7(2, 0.2), NDM-9(1, 0.1), NDM-19(1, 0.1) 695
India NDM-1(222, 92.8), NDM-4(12, 5.0), NDM-5(4, 1.6), NDM-10(1, 0.4) 239
Saudi Arabia NDM-1(152, 100) 152
Iran NDM-1(115, 93.4), NDM-6(3, 2.4), NDM-7(5, 4) 123
Singapore NDM-1(65, 98.4), NDM-7(1, 1.5) 66
Korea NDM-1(63, 100) 63
Thailand NDM-1(58, 93.5), NDM-4(2, 3.2), NDM-5(1, 1.6), NDM-9(1, 1.6) 62
Pakistan NDM-1(33, 100) 33
Malaysia NDM-1(25, 100) 25
Japan NDM-1(20, 100) 20
Israel NDM-1(19, 100) 19
Yemen NDM-1(16, 100) 16
Kuwait NDM-1(14, 100) 14
Myanmar NDM-1(9, 90), NDM-4(1, 10) 10
Oman NDM-1(7, 100) 7
Taiwan NDM-1(7, 100) 7
Bangladesh NDM-1(9, 100) 9
Arab Emirates NDM-1(8, 88.8), NDM-5(1, 11.1) 9
Iraq NDM-1(3, 100) 3
Phlippines NDM-1(1, 100) 1
Total NDM-1(1370, 87), NDM-4(15, 0.9), NDM-5(163, 10,3), NDM-6(13, 0.8), NDM-7(8, 0.5), NDM-9(2, 0.1),
NDM-10(1, 0.06), NDM-19(1, 0.06)
1573
Table 4
Distribution of New Delhi metallo-β-lactamase (NDM)-producing Klebsiella
pneumoniae isolated from clinical samples in different countries of Europe.
Country NDM type [n (%)] Total Na
Turkey NDM-1(93, 100) 93
Greece NDM-1(78, 100) 78
Bulgaria NDM-1(65, 100) 65
Estonia NDM-1(51, 100) 51
Russia NDM-1(34, 100) 34
UK NDM-1(26, 100) 26
France NDM-1(22, 95.6), NDM-5(1, 4.4) 23
Italy NDM-1(22, 100) 22
Poland NDM-1(22, 100) 22
Sweden NDM-1(21, 100) 21
Germany NDM-1(20, 100) 20
Norway NDM-1(11, 100) 11
Ireland NDM-1(9, 100) 9
Croatia NDM-1(9, 100) 9
England NDM-1(2, 100) 2
Spain NDM-1(1, 50), NDM-5(1, 50) 2
Netherland NDM-1(1, 100) 1
Serbia NDM-1(1, 100) 1
Finland NDM-1(1, 100) 1
Total NDM-1(489, 99), NDM-5(2, 0.4) 491
Table 5
Distribution of New Delhi metallo-β-lactamase (NDM)-producing Klebsiella pneumoniae isolated from clinical samples in different countries of America, Africa and Oceania.
Country NDM type [n (%)] Total Na
America
USA NDM-1(155, 98), NDM-5(2, 1.2), NDM-7(1, 0.6) 158
Mexico NDM-1(48, 100) 48
Canada NDM-1(7, 77), NDM-7(2, 22) 9
Brazil NDM-1(5, 100) 5
Chile NDM-1(1, 100) 1
Total NDM-1(216, 97.7), NDM-5(2, 0.9), NDM-7 (3, 1.3) 221
Africa
South Africa NDM-1(39, 100) 39
Tunisia NDM-1(27, 100) 27
Uganda NDM-1(24, 100) 24
Egypt NDM-1(21, 95), NDM-2(1, 4.5) 22
Angola NDM-1(9, 60), NDM-5(6, 40) 15
Morocco NDM-1(7, 100) 7
Gabon NDM-7(3, 100) 3
Total NDM-1(127, 92.7), NDM-2(1, 0.7), NDM-5(6, 4.3), NDM-7(3, 2.2) 137
Oceania
Australia NDM-1(9, 100) 9
Newzelland NDM-1(1, 100) 1
Total NDM-1(10, 80) 10
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Fig. 4. Distribution of NDM variants reported in K. penumoniae strains isolated from human clinical samples among different continents based on published studies.
Fig. 5. Time trend of the frequency of the various NDM variants of the carrying strains from 2009-2019.
Fig. 6. Distribution of STs of NDM-producing K. penumoniae strains isolated from human clinical samples among different continents based on published studies.
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frequency of blaNDM in Europe was around 16.8%, with the highest
dissemination of the blaNDM-1 variant in Romania, Bulgaria, Poland,
Italy, France, Germany, Turkey, Serbia, Greece, London, Croatia,
Ukraine, Ireland and Azerbaijan. In this continent NDM-4 was
reported in Italy, while NDM-5 and NDM-7 were only reported in
two countries (Denmark and France). Khan et al. showed that the
frequency of blaNDM-1 in America was around 10.8%. The highest
volume of blaNDM-1 was reported in Brazil (as the main reservoir)
while Mexico city, Georgia, Colorado, Paraguay, California, Florida,
Illinois, Jamaica, Pennsylvania, Argentina, Ecuador and Uruguay
were considered as areas with the lowest frequency of blaNDM-1.
The frequency of blaNDM-1 was 10.8% in Africa with a high
distribution level in Algeria, whereas KwaZulu-Natal, Greater
Johannesburg Area, Madagascar, Tunisia, Egypt and Libya showed
lower frequencies of blaNDM-1 producers. NDM-5 was identified in
Algeria. We investigated the frequency of STs of NPKP in strains
from human clinical specimens worldwide. NPKP are found among












































M. Safavi, N. Bostanshirin, B. Hajikhani et al. / Journal of Global Antimicrobial Resistance 23 (2020) 420–429ifferent STs. According to the results of our study Asia, Europe,
frica, Oceania and America reported the highest number of STs
espectively. Also, most of the reported STs were associated with
laNDM-1 and blaNDM-5. Most of the STs reported in Asia, Europe,
merica, Africa and Oceania were ST290, ST11, ST22, ST147 and
T14, respectively. ST11 has also been reported as a common type
n many studies [36–38]. It is important to note that ST11 is the
ominant ST of carbapenem-resistant K. pneumoniae in China
hich is frequently related to blaKPC-2 rather than blaNDM [39]. Our
esults also indicate that ST11 is the most common ST among NPKP
rom clinical samples. ST14 has been often reported as one of the
ost common type of NPKP in many studies [40,41]. In the current
eview, ST14 was reported in Asia (India, China, Singapore, Israel
nd Pakistan), Europe (Turkey) and Oceania (Australia). The
arbapenem-resistant K. pneumoniae ST258, which has worldwide
istribution, carries most of the blaKPC-2 or blaKPC-3 [42,43]. ST258
as found in China and the UK carrying blaNDM-5 and blaNDM-1
espectively. In general, STs 11, 290, 147, 340, 15 and 278 were
mong the most abundant types of STs among NPKP isolated from
uman clinical specimens worldwide. Almost 80% of all types of
Ts were found just in one country. It is noteworthy that not all
rticles that met the inclusion criteria listed STs in NPKP isolated
rom human clinical specimens so the frequency of STs between
ontinents and different countries may vary. In addition, migration
r other forms of travelling between regions may be an important
ause in the spread of certain STs. We show that the most frequent
laNDM genes associated with the reported STs were blaNDM-1,
laNDM-5 and blaNDM-7 on all continents. Also, blaNDM-1 is the only
laNDM variant which associated with all the common STs
entioned above. NPKP strains are spreading around the world
44]. Despite numerous efforts, this remains a major challenge to
he international community and a threat to public health. There is
urrently no consensus treatment for NDM-positive infections in
he clinic. Still many agents are being evaluated with different
echanisms of action. According to different reports, polymyxins
ave recently been used as primary drugs in the treatment of
in the fight against NDM. Therefore, increasing awareness of
infection control and adherence to infection control protocols in
health care is essential. Among the factors that significantly
increase the strains of NPKP strains are: overuse of antibiotics,
failure to implement preventive health measures, inadequate staff
training and lack of hospital infection control programs. There are
limitations to our study. First, since there is insufficient informa-
tion from many countries, we have not been able to assess the
frequency of NPKP on a truly global scale. Second, as some
countries do not systematically monitor for the occurrence of
resistant bacteria such as K. pneumoniae, the number of reported
NPKP isolated from clinical specimens may not be fully accurate.
Further, failure to comply with the guidelines on the isolation and
identification of bacteria resistant to antimicrobial agents can lead
to wrong results. Finally, despite the importance of the impact of
NDM on mortality, studies on this issue are rare and the necessity
of such investigates is clear.
5. Conclusion
It can be concluded that due to the relatively high frequency of
NPKP strains, especially the most common clonal groups, the
attention of various groups involved in clinical care is important.
Many infection control measures against carbapenem-resistant
Gram-negative bacteria may be based on relatively poor quality
studies (e.g. using inappropriate diagnostic methods or low sample
size) and designing more appropriate studies are needed to define
more effective preventative and therapeutic actions. Finally,
although many guidelines agree that resistance to carbapenemases
should be considered as a general principle in terms of infection
control, blaNDM and blaKPC-positive strains have significant differ-
ences (in terms of virulence or resistance to multi drugs). Finally, it
is imperative that the international health community must
cooperate to overcome this threat to public health.
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